PHOTOCURE ASA (PHO.OL) Stock Fundamental Analysis
OSL:PHO - Euronext Oslo - NO0010000045 - Common Stock - Currency: NOK
Taking everything into account, PHO scores 4 out of 10 in our fundamental rating. PHO was compared to 53 industry peers in the Pharmaceuticals industry. PHO has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, PHO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PHO had positive earnings in the past year.
PHO had a positive operating cash flow in the past year.
In the past 5 years PHO reported 4 times negative net income.
Of the past 5 years PHO 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of PHO (0.30%) is worse than 62.26% of its industry peers.
PHO has a worse Return On Equity (0.45%) than 64.15% of its industry peers.
Looking at the Return On Invested Capital, with a value of 1.79%, PHO is doing worse than 64.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.3% | ||
| ROE | 0.45% | ||
| ROIC | 1.79% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHO's Profit Margin of 0.40% is on the low side compared to the rest of the industry. PHO is outperformed by 62.26% of its industry peers.
Looking at the Operating Margin, with a value of 2.64%, PHO is doing worse than 64.15% of the companies in the same industry.
PHO's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 93.97%, PHO belongs to the top of the industry, outperforming 92.45% of the companies in the same industry.
PHO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.64% | ||
| PM (TTM) | 0.4% | ||
| GM | 93.97% |
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHO is destroying value.
The number of shares outstanding for PHO remains at a similar level compared to 1 year ago.
Compared to 5 years ago, PHO has more shares outstanding
Compared to 1 year ago, PHO has an improved debt to assets ratio.
2.2 Solvency
PHO has an Altman-Z score of 4.68. This indicates that PHO is financially healthy and has little risk of bankruptcy at the moment.
PHO has a better Altman-Z score (4.68) than 79.25% of its industry peers.
There is no outstanding debt for PHO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.68 |
ROIC/WACC0.21
WACC8.45%
2.3 Liquidity
A Current Ratio of 3.81 indicates that PHO has no problem at all paying its short term obligations.
PHO has a Current ratio of 3.81. This is amongst the best in the industry. PHO outperforms 98.11% of its industry peers.
PHO has a Quick Ratio of 3.44. This indicates that PHO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PHO (3.44) is better than 96.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.44 |
3. Growth
3.1 Past
The earnings per share for PHO have decreased strongly by -86.67% in the last year.
The Revenue has been growing slightly by 3.95% in the past year.
The Revenue has been growing by 13.29% on average over the past years. This is quite good.
EPS 1Y (TTM)-86.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.97%
Revenue 1Y (TTM)3.95%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%6.19%
3.2 Future
Based on estimates for the next years, PHO will show a very strong growth in Earnings Per Share. The EPS will grow by 190.44% on average per year.
The Revenue is expected to grow by 14.98% on average over the next years. This is quite good.
EPS Next Y896.78%
EPS Next 2Y264.59%
EPS Next 3Y190.44%
EPS Next 5YN/A
Revenue Next Year11.38%
Revenue Next 2Y11.91%
Revenue Next 3Y11.59%
Revenue Next 5Y14.98%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 2510.00, PHO can be considered very expensive at the moment.
Based on the Price/Earnings ratio, PHO is valued a bit more expensive than the industry average as 69.81% of the companies are valued more cheaply.
PHO's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.25.
PHO is valuated rather expensively with a Price/Forward Earnings ratio of 24.70.
Based on the Price/Forward Earnings ratio, PHO is valued a bit more expensive than the industry average as 62.26% of the companies are valued more cheaply.
The average S&P500 Price/Forward Earnings ratio is at 22.15. PHO is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2510 | ||
| Fwd PE | 24.7 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHO indicates a slightly more expensive valuation: PHO is more expensive than 64.15% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHO indicates a somewhat cheap valuation: PHO is cheaper than 60.38% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.05 | ||
| EV/EBITDA | 25.22 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PHO's earnings are expected to grow with 190.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.8
PEG (5Y)N/A
EPS Next 2Y264.59%
EPS Next 3Y190.44%
5. Dividend
5.1 Amount
No dividends for PHO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:PHO (5/30/2025, 7:00:00 PM)
50.2
+0.5 (+1.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners50.48%
Inst Owner ChangeN/A
Ins Owners1.94%
Ins Owner ChangeN/A
Market Cap1.36B
Analysts82.5
Price Target82.88 (65.1%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-94.41%
Min EPS beat(2)-203.96%
Max EPS beat(2)15.13%
EPS beat(4)2
Avg EPS beat(4)-37.97%
Min EPS beat(4)-203.96%
Max EPS beat(4)47.82%
EPS beat(8)5
Avg EPS beat(8)40.12%
EPS beat(12)6
Avg EPS beat(12)-9.06%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.7%
Min Revenue beat(2)-5.24%
Max Revenue beat(2)-2.17%
Revenue beat(4)1
Avg Revenue beat(4)-3.95%
Min Revenue beat(4)-9.78%
Max Revenue beat(4)1.4%
Revenue beat(8)3
Avg Revenue beat(8)-3.64%
Revenue beat(12)6
Avg Revenue beat(12)-2.7%
Revenue beat(16)7
Avg Revenue beat(16)-4.28%
PT rev (1m)-3.27%
PT rev (3m)-18.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)6.5%
Revenue NQ rev (1m)-6.75%
Revenue NQ rev (3m)-7.41%
Revenue NY rev (1m)-2.71%
Revenue NY rev (3m)2.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2510 | ||
| Fwd PE | 24.7 | ||
| P/S | 2.56 | ||
| P/FCF | 21.05 | ||
| P/OCF | 17.97 | ||
| P/B | 2.89 | ||
| P/tB | 5.77 | ||
| EV/EBITDA | 25.22 |
EPS(TTM)0.02
EY0.04%
EPS(NY)2.03
Fwd EY4.05%
FCF(TTM)2.38
FCFY4.75%
OCF(TTM)2.79
OCFY5.56%
SpS19.64
BVpS17.4
TBVpS8.71
PEG (NY)2.8
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.3% | ||
| ROE | 0.45% | ||
| ROCE | 2.32% | ||
| ROIC | 1.79% | ||
| ROICexc | 3.13% | ||
| ROICexgc | 9.81% | ||
| OM | 2.64% | ||
| PM (TTM) | 0.4% | ||
| GM | 93.97% | ||
| FCFM | 12.14% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-14.8%
ROICexc growth 3YN/A
ROICexc growth 5Y-32.88%
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
F-Score5
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 38.09% | ||
| Cap/Sales | 2.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 175.53% | ||
| Profit Quality | 3024.79% | ||
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.44 | ||
| Altman-Z | 4.68 |
F-Score5
WACC8.45%
ROIC/WACC0.21
Cap/Depr(3y)33%
Cap/Depr(5y)196.94%
Cap/Sales(3y)1.85%
Cap/Sales(5y)14.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-86.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.97%
EPS Next Y896.78%
EPS Next 2Y264.59%
EPS Next 3Y190.44%
EPS Next 5YN/A
Revenue 1Y (TTM)3.95%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%6.19%
Revenue Next Year11.38%
Revenue Next 2Y11.91%
Revenue Next 3Y11.59%
Revenue Next 5Y14.98%
EBIT growth 1Y-61.13%
EBIT growth 3YN/A
EBIT growth 5Y-13.75%
EBIT Next Year105.28%
EBIT Next 3Y59.66%
EBIT Next 5YN/A
FCF growth 1Y1030.99%
FCF growth 3Y47.91%
FCF growth 5Y27.04%
OCF growth 1Y590.65%
OCF growth 3Y47.56%
OCF growth 5Y30.02%